{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:50:53Z","timestamp":1767181853524},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T00:00:00Z","timestamp":1295913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s12032-010-9790-y","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T14:20:38Z","timestamp":1295878838000},"page":"212-214","source":"Crossref","is-referenced-by-count":6,"title":["Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Haitam","family":"Nasrallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nissim","family":"Haim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"issue":"5 Suppl 2","key":"9790_CR1","first-page":"35","volume":"20","author":"AB Sandler","year":"2006","unstructured":"Sandler AB. No dermatologic adverse events associated with anti-EGFR therapy. Oncology. 2006;20(5 Suppl 2):35\u201340.","journal-title":"Oncology"},{"key":"9790_CR2","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549\u201356.","journal-title":"J Clin Oncol"},{"key":"9790_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/MO:23:2:161","volume":"23","author":"M Tsuboi","year":"2006","unstructured":"Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol. 2006;23:161\u201370.","journal-title":"Med Oncol"},{"key":"9790_CR4","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/cncr.21808","volume":"106","author":"SM Belknap","year":"2006","unstructured":"Belknap SM, et al. Clinical features and correlates of gemcitabine associated lung injury: findings from the RADAR project. Cancer. 2006;106:2051\u20137.","journal-title":"Cancer"},{"key":"9790_CR5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","volume":"15","author":"HA Burris 3rd","year":"2010","unstructured":"Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15:1227\u201337.","journal-title":"Oncologist"},{"key":"9790_CR6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JTO.0b013e3181dab0dd","volume":"5","author":"Y Togashi","year":"2010","unstructured":"Togashi Y, Masago K, Mishima M, Fukudo M, Inui K. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration. J Thorac Oncol. 2010;5:924\u20135.","journal-title":"J Thorac Oncol"},{"key":"9790_CR7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960\u20136.","journal-title":"J Clin Oncol"},{"key":"9790_CR8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","volume":"25","author":"U Gatzemeier","year":"2007","unstructured":"Gatzemeier U, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol. 2007;25:1545\u201352.","journal-title":"J Clin Oncol"},{"key":"9790_CR9","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2008.21.5541","volume":"27","author":"TS Mok","year":"2009","unstructured":"Mok TS, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:5080\u20137.","journal-title":"J Clin Oncol"},{"key":"9790_CR10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0761-8417(07)78425-0","volume":"63","author":"A Bonnichon","year":"2007","unstructured":"Bonnichon A, et al. Favorable outcome of gemcitabine-induced acute respiratory distress syndrome. Rev Pneumol Clin. 2007;63:379\u201383.","journal-title":"Rev Pneumol Clin"},{"key":"9790_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1191\/1078155205jp158cr","volume":"11","author":"KA Tammaro","year":"2005","unstructured":"Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract. 2005;11:127\u201330.","journal-title":"J Oncol Pharm Pract"},{"key":"9790_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/CAD.0b013e3281ceabec","volume":"18","author":"S Boeck","year":"2007","unstructured":"Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs. 2007;18:1109\u201311.","journal-title":"Anticancer Drugs"},{"key":"9790_CR13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-7-150","volume":"7","author":"D Makris","year":"2007","unstructured":"Makris D, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer. 2007;7:150.","journal-title":"BMC Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9790-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9790-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:51Z","timestamp":1559442171000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9790-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,25]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["9790"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9790-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,25]]}}}